Mayo Clinic Research Suggests Women Over 65 Be Offered Hereditary Cancer Genetic Testing
The study results suggest that perhaps all women with breast cancer, including those diagnosed over age 65, should be offered hereditary breast cancer testing.
Category: Breast
Breast
Latest
Breast
Latest
Oncotype DX Test Can Spare Chemotherapy for Women with Certain Breast Cancers
Data from RxPONDER trial successfully defined the benefit of chemotherapy in early-stage, node-positive breast cancer patients with Oncotype DX Breast Recurrence Score results of 0 to 25.
Breast
Latest
Multicancer Blood Test, Combined with Imaging, Shows Promise as Screen for Cancer
The blood test followed by PET-CT imaging was 99.6% specific for cancer.
FDA Approves Expanded Indications for FoundationOne CDx
FoundationOne CDx is the only FDA-approved comprehensive genomic profiling test for all solid tumors that incorporates multiple companion diagnostics.
Read MoreT2 Biosystems Appoints Industry Veteran John Sperzel as Chief Executive Officer
T2 Biosystems has announced the appointment of diagnostics industry veteran John Sperzel as president and chief executive officer, succeeding John McDonough, who will continue with his board leadership role, serving as nonexecutive chairman.
Read More
New Directions in Triple-Negative Breast Cancer Diagnostics
A novel PD-L1 assay advances the promise of precision medicine.
Read More
Susan G. Komen Unveils Nearly $26 Million Investment in Research with a Focus on Metastatic Breast Cancer
The 2019 grants focus on key areas that will help the organization halve the current number of breast cancer deaths in the United States by 2026.
Read More
Roche Launches Companion Diagnostic to Identify Triple-Negative Breast Cancer Patients Eligible for Treatment with Tecentriq
The Ventana PD-L1 assay helps identify triple-negative breast cancer patients most likely to benefit from treatment with Tecentriq plus chemotherapy.
Read More
Expanding Genetic Testing Guidelines Could Identify More Patients with Increased Risks of Cancer
Current testing guidelines miss new gene-cancer associations that have the potential to impact care, study says.
Read MoreUS Preventive Services Task Force Issues Final Recommendation on BRCA-Related Cancer Prevention
Some women may benefit from risk assessment, counseling, and testing for rare genetic mutations, says USPSTF.
Read More
New Liquid Biopsy Blood Test Improves Breast Cancer Diagnostics
The TARDIS test could help avoid unnecessary surgeries and enable physicians to continuously monitor cancer.
Read More
BluePrint Identifies Genomic Subtypes for African-American Breast Cancer Patients
New data underscore the importance of genomic profiling for African-American women with breast cancer, whose unique tumor biology can sometimes lead to poorer prognoses than those for Caucasian women.
Read More
Study Confirms Disparities in Triple-Negative Breast Cancer Diagnoses
Women of color and young women may face elevated risks of developing triple-negative breast cancers.
Read More
Liquid Biopsies Guide Improved Cancer Treatment
Monitoring cancer therapy in real time enables physicians to make smarter treatment decisions.
Read MoreASCO Updates Endorsement of MammaPrint for Early-Stage Node-Positive Breast Cancer Patients
MammaPrint breast cancer risk of recurrence test is the only molecular diagnostic indicated for use with patients who have breast cancer that has spread to their lymph nodes.
Read MoreStudy Demonstrates Cost-Effectiveness of EndoPredict for Breast Cancer
The EndoPredict test is more than twice as cost-effective as Oncotype Dx for predicting a patient’s recurrence of breast cancer.
Read MorePreludeDx Assay Stratifies Recurrence Risk for Early-Stage Breast Cancer Patients
The radiogenomic DCISionRT test helps to tailor treatments according to each patient’s biologic risk profile, helping to avoid under- and overtreatment.
Read MoreSaga Raises $4.1 Million to Advance Ultrasensitive Liquid Biopsies
The funds will be used to accelerate commercialization of Saga’s portfolio of kits and services, continue development of new products, and perform prospective clinical studies.
Read More